Acumen Pharmaceuticals (ABOS) Free Cash Flow (2020 - 2026)
Acumen Pharmaceuticals (ABOS) reported Free Cash Flow of -$24.1 million for Q1 2026, up 29.45% on a YoY basis from -$18.6 million in Q1 2025, and down 26.35% sequentially from -$19.1 million in Q4 2025.
Acumen Pharmaceuticals (ABOS) Free Cash Flow (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals (ABOS) has 7 years of Free Cash Flow data on file, last reported at -$24.1 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 29.45% year-over-year to -$24.1 million; the trailing twelve-month figure through Mar 2026 stood at -$105.6 million (down 2.92% YoY), and the FY2025 full-year result was -$115.6 million, down 34.09% from the prior year.
- Free Cash Flow retreated to -$24.1 million in Q1 2026, from -$19.1 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$6.5 million in Q2 2022 to a low of -$34.2 million in Q1 2025.
- A 5-year average of -$17.9 million and a median of -$16.6 million in 2024 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow sank 250.55% in 2022 and grew 29.83% in 2025, its largest moves.
- Tracing ABOS's Free Cash Flow over 5 years: stood at -$11.2 million in 2022, then grew by 25.89% to -$8.3 million in 2023, then sank by 226.79% to -$27.2 million in 2024, then gained by 29.83% to -$19.1 million in 2025, then fell by 26.35% to -$24.1 million in 2026.
- Business Quant data shows ABOS's Free Cash Flow at -$24.1 million in Q1 2026, -$19.1 million in Q4 2025, and -$30.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -354.95 Mn |
| 10 | Acumen Pharmaceuticals | 140.98 Mn | 140.98 Mn | - | -24.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.13 Mn |
| Mar 31, 2026 | -24.13 Mn |
| Dec 31, 2025 | -19.10 Mn |
| Dec 31, 2025 | -19.10 Mn |
| Sep 30, 2025 | -30.49 Mn |
| Sep 30, 2025 | -30.49 Mn |
| Jun 30, 2025 | -31.84 Mn |
| Jun 30, 2025 | -31.84 Mn |
| Mar 31, 2025 | -34.20 Mn |
| Mar 31, 2025 | -34.20 Mn |
| Dec 31, 2024 | -27.22 Mn |
| Dec 31, 2024 | -27.22 Mn |
| Sep 30, 2024 | -24.60 Mn |
| Sep 30, 2024 | -24.60 Mn |
| Jun 30, 2024 | -16.55 Mn |
| Jun 30, 2024 | -16.55 Mn |
| Mar 31, 2024 | -17.87 Mn |
| Mar 31, 2024 | -17.87 Mn |
| Dec 31, 2023 | -8.33 Mn |
| Dec 31, 2023 | -8.33 Mn |